Abstract: The present invention generally relates to compounds that inhibit haematopoietic-prostaglandin D2 synthase (H-PGDS), to compositions containing them and to their use in treating or preventing conditions and diseases associated with H-PGDS, such as allergies and inflammation.
Type:
Grant
Filed:
June 1, 2011
Date of Patent:
December 1, 2015
Assignee:
The University of Queensland
Inventors:
Mark Leslie Smythe, Jack Urquhart Flanagan
Abstract: Disclosed is a phosphorescent organometallic complex having: a 6-membered aromatic heterocycle having a nitrogen atom; iridium or platinum to which the nitrogen atom coordinates; and an aryl group which is bonded to an ?-carbon of the nitrogen atom and is ortho-metalated with the iridium or platinum, where at least one of the aromatic heterocycle and the aryl group has an alicyclic hydrocarbon having an intramolecular carbon-carbon bridged bond as a substituent. The ability of the bulky structure of the alicyclic hydrocarbon to inhibit aggregation of the organometallic complex, concerted with the strong electron-donating property of the alicyclic hydrocarbon to the aromatic heterocycle or the aryl group, contributes to the increase in absorption coefficient and phosphorescent efficiency of the organometallic complex. The improved absorption coefficient and the phosphorescent efficiency allow the formation of a light-emitting element with excellent external quantum efficiency over 25%.
Type:
Grant
Filed:
April 13, 2012
Date of Patent:
December 1, 2015
Assignee:
Semiconductor Energy Laboratory Co., Ltd.
Inventors:
Hideko Inoue, Hiromi Nowatari, Satoshi Seo
Abstract: The present invention provides compounds of Formula (I), as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.
Type:
Grant
Filed:
March 29, 2013
Date of Patent:
December 1, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jennifer X. Qiao, Carol Hui Hu, Tammy C. Wang, Ji Jiang
Abstract: A dye compound of formula 1: where R and R? are substituents independently selected from the group consisting of a hydrogen atom, C1 to C4 alkyl and a solubilizing moiety comprising a substituted or unsubstituted C10 to C70 hydrocarbyl group. At least one of R and R? is not a hydrogen atom or C1 to C4 alkyl. R? and R?? can be independently selected from the group consisting of a hydrogen atom, C1 to C6 alkyl groups or halogens; and X is a squaric acid moiety. A property of the dye compound is that it absorbs radiation having a wavelength in the range of about 700 nm to about 1400 nm.
Type:
Grant
Filed:
August 26, 2013
Date of Patent:
November 24, 2015
Assignee:
XEROX CORPORATION
Inventors:
Jeffrey H. Banning, Jule W. Thomas, Jr., Bo Wu, Stephan V. Drappel
Abstract: The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Type:
Grant
Filed:
March 7, 2014
Date of Patent:
November 10, 2015
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Sacha Holland, Rao Kolluri, Salvador Alvarez, Matthew Duncton, Rajinder Singh, Jing Zhang, Esteban Masuda
Abstract: The present invention provides for compounds of formula (I): wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.
Type:
Grant
Filed:
July 13, 2012
Date of Patent:
November 10, 2015
Assignee:
NOVARTIS AG
Inventors:
Atwood Kim Cheung, Donovan Noel Chin, Jianmei Fan, Karen Marie Miller-Moslin, Michael David Shultz, Troy D Smith, Ronald Charles Tomlinson, Bakary-Barry Toure, Michael Scott Visser, Zhuoliang Chen
Abstract: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.
Type:
Grant
Filed:
January 22, 2009
Date of Patent:
November 3, 2015
Assignee:
Dow AgroSciences LLC
Inventors:
Zoltan L. Benko, Timothy Boebel, Nneka T. Breaux, Kristy Bryan, George E. Davis, Jeffrey B. Epp, Beth Lorsbach, Timothy P. Martin, Kevin G. Meyer, Bassam S. Nader, W. John Owen, Mark A. Pobanz, James M. Ruiz, Frisby D. Smith, Michael T. Sullenberger, Jeffery D. Webster, Chenglin Yao, David H. Young
Abstract: The present invention relates to substituted pyrazole-containing compounds of formula (I), and the stereoisomers and salts thereof, wherein the substituents are as defined in the description. The present invention further relates to a method for combating or controlling invertebrate pests, to a method for protecting plant propagation material and/or the plants which grow therefrom, to plant propagation material comprising at least one compound according to the present invention, to a method for treating or protecting an animal from infestation or infection by parasites, to a process for the preparation of a composition for treating infested or infected animals and/or for protecting animals against infestation or infection by parasites, and to a compound according to the invention for use as a medicament.
Type:
Grant
Filed:
April 29, 2013
Date of Patent:
November 3, 2015
Assignee:
BASF SE
Inventors:
Karsten Korber, Florian Kaiser, Gemma Veitch, Wolfgang Von Deyn, Nina Gertrud Bandur, Joachim Dickhaut, Arun Narine, Deborah L. Culbertson, Paul Neese, Koshi Gunjima
Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Type:
Grant
Filed:
January 29, 2013
Date of Patent:
November 3, 2015
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Alessandra Bartolozzi, Zhidong Chen, Jonathon Alan Dines, Ho Yin Lo, Pui Leng Loke, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function by contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize hedgehog activity.
Abstract: This invention relates to novel crystalline lopinavir/surfactant adducts, methods for their preparation, therapeutic uses of those crystalline lopinavir/surfactant adducts, and pharmaceutical compositions containing them or made from them.
Type:
Grant
Filed:
December 16, 2011
Date of Patent:
November 3, 2015
Assignee:
ABBVIE INC.
Inventors:
Yuchuan Gong, Geoff G. Zhang, Matthias Degenhardt, Markus Maegerlein
Abstract: Novel compounds of structure Formula I: (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
November 3, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Matthias Broekema, Gang Wu, Dean A. Wacker
Abstract: The present invention relates to tyrosine kinase inhibitors that contain a zinc-binding moiety and their use in the treatment of tyrosine related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
October 27, 2015
Assignee:
Curis, Inc.
Inventors:
Xiong Cai, Changgeng Qian, Stephen Gould, Haixiao Zhai
Abstract: Arylalkyl esters of 4-aminopicolinic acids and 6-amino-4-pyrimidinecarboxylates are herbicides for control of weeds especially those species common to rice and wheat cropping systems and in pasture management programs.
Type:
Grant
Filed:
October 9, 2014
Date of Patent:
October 27, 2015
Assignee:
Dow AgroSciences LLC
Inventors:
Carla N. Yerkes, Christian T. Lowe, Joseph D. Eckelbarger, Jeffrey B. Epp, Katherine A. Guenthenspberger, Thomas L. Siddall, Paul R. Schmitzer
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Type:
Grant
Filed:
February 19, 2015
Date of Patent:
October 20, 2015
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Rajinder Singh, Ankush Argade, Donald G. Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
Abstract: The present invention provides a compound of Formula (I) as described herein, or a pharmaceutically acceptable salt thereof. The present invention also provides pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
Type:
Grant
Filed:
July 3, 2012
Date of Patent:
October 20, 2015
Assignee:
Merck Sharp & Dohme Corp.
Inventors:
Craig Boyle, William Greenlee, Samuel Chackalamannil, Claire Lankin
Abstract: Disclosed is a compound of (aminophenylamino) pyrimidyl benzamides and a synthesis method thereof. The compound has Btk-inhibition activity and can be used to treat autoimmune diseases, heteroimmune diseases, cancers or thromboembolic diseases.
Type:
Grant
Filed:
October 25, 2012
Date of Patent:
October 6, 2015
Assignees:
Peking University Shenzhen Graduate School, Beijing Reciprocapharmaceuticals Co. Ltd.
Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
Type:
Grant
Filed:
September 8, 2014
Date of Patent:
October 6, 2015
Assignee:
Millennium Pharmaceuticals, Inc.
Inventors:
Christopher F. Claiborne, Stephen Critchley, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Stepan Vyskocil, Gabriel S. Weatherhead
Abstract: This invention comprises the novel compounds of formula (I) wherein n, R1, R2, R3, R4, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.
Type:
Grant
Filed:
February 21, 2014
Date of Patent:
October 6, 2015
Assignee:
Janssen Pharmaceutica NV
Inventors:
Kristof Van Emelen, Marc Gustaaf Celine Verdonck, Sven Franciscus Anna Van Brandt, Patrick Rene Angibaud, Lieven Meerpoel, Alexey Borisovich Dyatkin